Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

AstraZeneca gets US boost for bladder cancer drug

Drug group gets "breakthrough therapy" designation for durvalumab in the US
AstraZeneca gets US boost for bladder cancer drug
AstraZeneca is said to have received three "breakthrough therapy" designations for cancer drugs

Shares in drug group AstraZeneca (LON:AZN) were healthier after it received a US boost for a bladder cancer treatment.

The stock rose 70.5p, or nearly 1.7%, to 4254.5p as the Food & Drug Administration (FDA) designated its durvalumab drug as a "breakthrough therapy".

Breakthrough therapy designation (BTD) is designed to speed up development of drugs for serious conditions which have shown encouraging early clinical results, improvements over existing treatments or potential to address significant unmet medical need.

AstraZeneca's senior vice-president and head of immuno-oncology in global medicines development, Robert Iannone, said: "Metastatic bladder cancer is an area of enormous unmet medical need.

"We are encouraged by this breakthrough therapy designation. We look forward to working closely with the FDA to bring durvalumab to bladder cancer patients as soon as possible."

The designation, based on early clinical data from a phase one trial in patients with advanced urothelial bladder cancer, is said to be the third BTD that AstraZeneca has received for an oncology medicine.

Phil-Waller.jpg


Register here to be notified of future AZN Company articles
View full AZN profile

AstraZeneca Timeline

Article
December 28 2015

Related Articles

Cancer
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.
Magnified view of cancer cells
April 19 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
Cancer
March 31 2016
This broad coverage protects the company's lead immunotherapy, ImMucin

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.